Marc Soco

Pretest and post-test counseling. (A) The components of pretest counseling. (B) The components of post-test counseling. The goals of the counseling session are depicted in rectangular shapes. Questions that the clinicians should ask themselves are depicted in the white clouds. VUS, variants of uncertain significance.

nice (and free) review of genetic testing and counselling in renal disease

journals.lww.com/kidney360/fu...

in @asnpublications.bsky.social #Kidney360

#NephSky #Genetics

Totally agree. But given the signal for reduced hypoK and SCD… tempting to think K might be contributing independently #NephJC

a woman is making a funny face and the words so sassy are above her face ALT: a woman is making a funny face and the words so sassy are above her face

#NephJC

Feels unlikely to be pure coincidence. Potassium may be part of the mechanism, not just a bystander #NephJC

In patients with CV disease, the “normal” range may be misleading
Mortality is actually higher at K⁺ 3.5–4.0 mmol/L
while high-normal levels (4.5–5.0) are associated with lower mortality 👀 #NephJC
pubmed.ncbi.nlm.nih....

Glad to have you here! Always great to hear from someone who’s been intentionally targeting higher potassium in practice. Looking forward for some insights #NephJC

Hey everyone! Marc here, joining from the Philippines. No COI #NephJC

🍌🥑Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations?

🎨 #Visualabstract by @jeyakumarmeyyappan.bsky.social

⏰ #NephJC chat on Jan 27, 9 pm EST

www.nephjc.com/news/2026/1/...

¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones?

🎨Resumen visual por @jeyakumarmeyyappan.bsky.social
✍️Traducido por @dramiliflores.bsky.social

www.nephjc.com/news/2026/1/...

POTCAST- K+ Pop and Arrhythmia Drop — NephJC This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

Oh, the weather outside is frightful 🥶🥶
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast

Top Stories in Nephrology 2025 — NephJC 2025 was rich in successful stories. Here are the top 10 that impressed our audience.

It's 2026!🎉
We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST.
Join us on TWITTER (it will always be Twitter to us).
Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down.
www.nephjc.com/news/2025/1/3/top-stories-in-nephrology-2025

1/10

Last #NephJC we discussed dialysis frequency in AKI-D #TenPostNephJC

We sought to answer an age-old question: Is less is really more? Or less is just simply what it is….less?

pubmed.ncbi.nlm.nih.gov/41201895/

If hemodynamically stable and non-oliguric, then probably no. Ultimately, we treat the patient, not the numbers… using labs to inform, not dictate, decisions #NephJC

a woman in a blue jacket is sitting in front of a door and says oh yes . ALT: a woman in a blue jacket is sitting in front of a door and says oh yes .

#NephJC Popular opinion:

Have you ever “withheld” dialysis because the patient looked good despite questionable labs?
Did you feel brave or nervous? 😅
We restrict fluids, potassium, phosphorus…
But what about restricting dialysis itself?
Let’s talk. #NephJC

Hi everyone ! Marc here from the Philippines 🇵🇭 sharing this “imprisonment” from Jerónimos Monastery in Lisbon 🇵🇹. From historic monasteries to modern trials, let’s LIBERATE-D our thinking. Looking forward to a great discussion! No COI. #NephJC

LIBERATE-D: El Resumen Visual — NephJC En pacientes con lesión renal aguda en diálisis, se evaluó si una estrategia más conservadora impacta en la recuperación renal. ¿Será que menos es más? Únete a la discusión del ensayo clínico LIBERATE...

Gracias! @dramiliflores.bsky.social #NephSky
LIBERATE-D: El Resumen Visual — #NephJC

www.nephjc.com/news/2025/12/14/liberate-d-el-resumen-visual

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

www.nephjc.com/news/...
Check out the excellent #NephJC summary by @msocomd.bsky.social and @sejalplakhani.bsky.social

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳
How soon should we withhold dialysis in AKI?
We're discussing the LIBERATE-D trial #NephSky
This one might just change your mind 🧠🧠
Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social
www.nephjc.com/news/liberated-aki

PISCES: The Visual Abstract — NephJC Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟 A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC! Check out the VA made by our master Brian...

Holy Mackerel! 🐟
🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴‍☠️ #NephJC
Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST
Check out the PISCES VA by @brianrifkin.bsky.social
www.nephjc.com/news/piscesva

1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....

a man in a suit and tie is applauding with the words good job written below him ALT: a man in a suit and tie is applauding with the words good job written below him

awesome job @shelliefravel.bsky.social !! #nephJC

T4d:

That’s all partners 🤠

From here until the end of the year we will be catching up on all the late-breaking and simultaneous publications from #KidneyWk 2025. 😮‍💨

Ain’t no party like a #NephJC party!

T4c: #NephJC

The rapid development of treatments for IgAN shows that nephrology can innovate like oncology and cardiology, to the benefit of our patients.

Some final words of wisdom from #KidneyWk 2025

KDIGO IgA Guidelines: A Patient Voice — NephJC We have a patient perspective on the new IgA Guidelines and what it means to live with IgA in these times.

T4a: #NephJC

We recently got to hear the patient voice from @jonathanpollack.bsk.social

About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.

T3c: #NephJC

The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.

a man in a wig and sunglasses is wearing headphones and an american flag scarf ALT: a man in a wig and sunglasses is wearing headphones and an american flag scarf

#nephJC

#NephJC

Sorry will remain a dream for a while!

We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials

#NephJC

Physical Accessibility of Medicines in Countries Hosting Trials for FDA Approvals This cross-sectional study aims to determine whether and when medicines receive market authorization in the countries where they are tested for US Food and Drug Administration approval, as well as tre...

Same here in 🇨🇦!

Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com

Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market

#NephJC